Analyst Reiterates Bullish Stance on Edgewise Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy EWTX?
Source: Fool
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her overweight rating on Edgewise Therapeutics, setting a $51 price target, which contributed to a 4% stock increase, significantly outperforming the S&P 500's 0.5% rise.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate EDG-7500 is currently in Phase 2 clinical trials, with results expected in Q2 of this year, and if approved, it will provide an innovative solution for hypertrophic cardiomyopathy, enhancing market competitiveness.
- Market Potential: Rahimi considers Edgewise one of Piper Sandler's best stock picks for this year, based on its leading cardiovascular drug development and the potential of other pipeline projects, indicating strong prospects in the biotech sector.
- Muscle Development Treatment: In addition to cardiovascular drugs, Edgewise is advancing Sevasemten, a treatment for muscular dystrophy, showcasing the company's research capabilities and market opportunities across multiple therapeutic areas.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EWTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EWTX
Wall Street analysts forecast EWTX stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.440
Low
16.00
Averages
38.14
High
51.00
Current: 30.440
Low
16.00
Averages
38.14
High
51.00
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On February 27, 2026, Edgewise Therapeutics granted 51,000 stock options to three new non-executive employees, aimed at attracting talent and strengthening the team, in accordance with the company's 2024 Inducement Equity Incentive Plan.
- Exercise Price Setting: Each inducement stock option has an exercise price of $30.44 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: Under the plan, 25% of the stock options will vest on each employee's one-year anniversary, with an additional 1/48th vesting monthly thereafter, designed to incentivize long-term retention and contribution to the company's growth.
- Company Background: Edgewise is a biopharmaceutical company focused on muscle diseases, developing novel therapeutics for muscular dystrophies and serious cardiac conditions, dedicated to improving the quality of life for patients and their families.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On February 27, 2026, Edgewise Therapeutics granted 51,000 stock options to three new non-executive employees, aimed at attracting talent and enhancing employee loyalty, in accordance with the company's 2024 Inducement Equity Incentive Plan.
- Exercise Price Set: Each stock option has an exercise price of $30.44 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: The vesting schedule stipulates that 25% of the options will vest on the one-year anniversary of each employee's start date, with an additional 1/48th vesting monthly thereafter, which is designed to improve employee retention during their tenure at the company.
- Company Background: Edgewise focuses on developing biopharmaceuticals for muscle diseases, with ongoing clinical trials for Sevasemten, a first-in-class oral fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, showcasing the company's deep expertise in muscle physiology.
See More
Edgewise Therapeutics Reports Q4 Results with Significant Cash Reserves
- Financial Performance: Edgewise Therapeutics reported a Q4 GAAP EPS of -$0.47, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Reserves: As of December 31, 2025, the company held approximately $530.1 million in cash, cash equivalents, and marketable securities, providing significant financial flexibility for future R&D and operational needs.
- Conference Presentation: Edgewise presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among investors and potentially paving the way for future financing and partnership opportunities.
- Clinical Trial Progress: The company reported positive mid-stage trial data for its heart disease therapy, suggesting that despite current financial struggles, favorable clinical outcomes may set the stage for key catalysts in Q2 2026.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Share Reduction Transaction: According to a SEC filing dated February 17, 2026, ORBIMED Advisors LLC sold 5,409,671 shares of Terns Pharmaceuticals for approximately $125 million, indicating a potential decrease in confidence regarding the company's future prospects.
- Holding Changes: Following this sale, ORBIMED retains 2,153,300 shares of Terns, with a value decrease of $30.20 million, reflecting fluctuations in market expectations for its clinical pipeline.
- Market Performance: As of February 17, 2026, Terns' stock price stood at $39.58, marking an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, showcasing strong market confidence in its biotech potential.
- Investor Focus: With upcoming clinical data releases, investors should monitor Terns' cash flow and trial results to assess whether its pipeline justifies the current high valuation, especially since robust data is crucial for sustaining valuation in the biotech sector.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Stake Reduction Size: ORBIMED Advisors LLC disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Terns Pharmaceuticals by 5,409,671 shares, with an estimated transaction size of $125.01 million, reflecting a cautious outlook on the company's future prospects.
- Position Value Change: Following this transaction, ORBIMED's position in Terns decreased to 2,153,300 shares, with a value drop of $30.20 million, indicating the market's sensitivity to fluctuations in the company's stock price.
- Asset Management Proportion: After the reduction, Terns now represents 1.78% of ORBIMED's reportable AUM, falling outside the top five holdings, which suggests a diminished significance in the investment portfolio.
- Market Performance Comparison: As of February 17, 2026, Terns' stock price stood at $39.58, reflecting an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, demonstrating strong market confidence in its clinical pipeline.
See More
Cormorant Increases MoonLake Stake Above 6%
- Stake Increase: Cormorant Asset Management disclosed on Tuesday that it has increased its stake in MoonLake Immunotherapeutics to 4.36 million shares, representing a 6.1% ownership, up from about 2 million shares in October 2025, indicating strong confidence in the company's future and potential stock price impact.
- Significant Stock Surge: Following the news of Cormorant's increased stake, MoonLake's shares jumped 11% on Tuesday, marking the largest rally in over a month, reflecting heightened market interest in a possible takeover and potentially attracting more investors.
- Market Sentiment Shift: Retail sentiment for MLTX on Stocktwits flipped from 'extremely bearish' to 'extremely bullish' with a 900% surge in message volume over 24 hours, indicating strong investor expectations for the company's future, which could further drive stock price increases.
- FDA Fast Track Progress: MoonLake's Sonelokimab received FDA Fast Track designation, with plans to pursue a biologics license application in the second half of 2026, highlighting the company's potential in the treatment space and likely drawing increased institutional investor interest in its long-term growth prospects.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On February 27, 2026, Edgewise Therapeutics granted 51,000 stock options to three new non-executive employees, aimed at attracting talent and strengthening the team, in accordance with the company's 2024 Inducement Equity Incentive Plan.
- Exercise Price Setting: Each inducement stock option has an exercise price of $30.44 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: Under the plan, 25% of the stock options will vest on each employee's one-year anniversary, with an additional 1/48th vesting monthly thereafter, designed to incentivize long-term retention and contribution to the company's growth.
- Company Background: Edgewise is a biopharmaceutical company focused on muscle diseases, developing novel therapeutics for muscular dystrophies and serious cardiac conditions, dedicated to improving the quality of life for patients and their families.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On February 27, 2026, Edgewise Therapeutics granted 51,000 stock options to three new non-executive employees, aimed at attracting talent and enhancing employee loyalty, in accordance with the company's 2024 Inducement Equity Incentive Plan.
- Exercise Price Set: Each stock option has an exercise price of $30.44 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: The vesting schedule stipulates that 25% of the options will vest on the one-year anniversary of each employee's start date, with an additional 1/48th vesting monthly thereafter, which is designed to improve employee retention during their tenure at the company.
- Company Background: Edgewise focuses on developing biopharmaceuticals for muscle diseases, with ongoing clinical trials for Sevasemten, a first-in-class oral fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, showcasing the company's deep expertise in muscle physiology.
See More
Edgewise Therapeutics Reports Q4 Results with Significant Cash Reserves
- Financial Performance: Edgewise Therapeutics reported a Q4 GAAP EPS of -$0.47, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Reserves: As of December 31, 2025, the company held approximately $530.1 million in cash, cash equivalents, and marketable securities, providing significant financial flexibility for future R&D and operational needs.
- Conference Presentation: Edgewise presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among investors and potentially paving the way for future financing and partnership opportunities.
- Clinical Trial Progress: The company reported positive mid-stage trial data for its heart disease therapy, suggesting that despite current financial struggles, favorable clinical outcomes may set the stage for key catalysts in Q2 2026.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Share Reduction Transaction: According to a SEC filing dated February 17, 2026, ORBIMED Advisors LLC sold 5,409,671 shares of Terns Pharmaceuticals for approximately $125 million, indicating a potential decrease in confidence regarding the company's future prospects.
- Holding Changes: Following this sale, ORBIMED retains 2,153,300 shares of Terns, with a value decrease of $30.20 million, reflecting fluctuations in market expectations for its clinical pipeline.
- Market Performance: As of February 17, 2026, Terns' stock price stood at $39.58, marking an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, showcasing strong market confidence in its biotech potential.
- Investor Focus: With upcoming clinical data releases, investors should monitor Terns' cash flow and trial results to assess whether its pipeline justifies the current high valuation, especially since robust data is crucial for sustaining valuation in the biotech sector.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Stake Reduction Size: ORBIMED Advisors LLC disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Terns Pharmaceuticals by 5,409,671 shares, with an estimated transaction size of $125.01 million, reflecting a cautious outlook on the company's future prospects.
- Position Value Change: Following this transaction, ORBIMED's position in Terns decreased to 2,153,300 shares, with a value drop of $30.20 million, indicating the market's sensitivity to fluctuations in the company's stock price.
- Asset Management Proportion: After the reduction, Terns now represents 1.78% of ORBIMED's reportable AUM, falling outside the top five holdings, which suggests a diminished significance in the investment portfolio.
- Market Performance Comparison: As of February 17, 2026, Terns' stock price stood at $39.58, reflecting an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, demonstrating strong market confidence in its clinical pipeline.
See More
Cormorant Increases MoonLake Stake Above 6%
- Stake Increase: Cormorant Asset Management disclosed on Tuesday that it has increased its stake in MoonLake Immunotherapeutics to 4.36 million shares, representing a 6.1% ownership, up from about 2 million shares in October 2025, indicating strong confidence in the company's future and potential stock price impact.
- Significant Stock Surge: Following the news of Cormorant's increased stake, MoonLake's shares jumped 11% on Tuesday, marking the largest rally in over a month, reflecting heightened market interest in a possible takeover and potentially attracting more investors.
- Market Sentiment Shift: Retail sentiment for MLTX on Stocktwits flipped from 'extremely bearish' to 'extremely bullish' with a 900% surge in message volume over 24 hours, indicating strong investor expectations for the company's future, which could further drive stock price increases.
- FDA Fast Track Progress: MoonLake's Sonelokimab received FDA Fast Track designation, with plans to pursue a biologics license application in the second half of 2026, highlighting the company's potential in the treatment space and likely drawing increased institutional investor interest in its long-term growth prospects.
See More
